MiniMed’s Nasdaq Debut Underwhelms Amid Market Jitters And Geopolitical Uncertainty
A turbulent market backdrop, geopolitical shock following the US and Israel striking Iran days before pricing, and a limited public float is likely to have weighed on investor appetite.
Medtech Insight - March 9, 2026

GDUFA IV: Sponsors May See ANDA Prioritization If Some Production Aspects Onshored
The FDA offered to relax the onshoring criteria to receive a priority ANDA review in GDUFA IV, but could drop another America First proposal.
Generics Bulletin - March 9, 2026

UniQure Leads Biotechs Heartened By Prasad’s Second FDA Exit
Shares have surged in companies who have fallen foul of Prasad’s stricter approach, but it is not clear whether a future successor will continue or reverse his policies.
Scrip - March 9, 2026

Avia Grows Nordic OTC Offering With Allderma
Avia Pharma has acquired fellow Swedish firm Allderma to add to its offering brands like Hårkontrol, Daxxin and Lactiplus.
HBW Insight - March 9, 2026

Lundbeck Shines Light On Amlenetug
The Phase III anti-alpha-synuclein antibody has the potential to become a first-in-class therapy for multiple system atrophy.
Scrip - March 9, 2026

Merck’s Oncology Portfolio Strategy Beyond Keytruda
Merck's post-Keytruda oncology strategy rests on three pillars – immune deepening, tissue targeting and tumor-intrinsic mechanisms – anchored by patient selection, AI-accelerated discovery and a KRAS bet that could define its next era.
In Vivo - March 9, 2026

Formycon Flags Missed Guidance Ahead Of The FY2025 Results Report
Deal after deal, Formycon was inching toward closing the gap in its annual guidance. Still, it was not enough to meet the goal, as the German biosimilars developer’s preliminary financial report reveals.
Generics Bulletin - March 9, 2026

Latest Tally Shows 1,821 FDA-Cleared Digital Health Tools
Recently published lists show that the US Food and Drug Administration had cleared almost 2,000 digital health tools by the end of 2025. Of these, well over half – 1,104 – were radiology devices incorporating AI. Find a full breakdown in these tables.
Medtech Insight - March 9, 2026

Deals Shaping The Medtech And Diagnostics Industries, February 2026
An interactive look at medtech and diagnostics deals made during February 2026. Data courtesy of Biomedtracker.
Medtech Insight - March 9, 2026

Ipsen To Pull Tazverik Following Safety Concerns
Ipsen will withdraw its anticancer, Tazverik, worldwide after its SYMPHONY?1 trial revealed cases of secondary hematologic malignancy.
Scrip - March 9, 2026

EMS To Bolster Brazilian Generics Position With $500m+ Medley Buyout
Brazil’s EMS has agreed to acquire Sanofi’s Medley generics business in a deal aimed at strengthening its position in the country’s off-patent medicines market, with the combined platform potentially reaching about 32% share pending regulatory approval.
Generics Bulletin - March 9, 2026

Biotech Britain Vs. The World
Industry leaders share how Britain can strengthen its biotech ecosystem, from capital and regulation to talent and ambition, and what the sector could look like by 2030.
In Vivo - March 9, 2026

Amphastar’s Secretive Inhaler Candidate Revealed As Atrovent HFA Generic After FDA Nod
Previously known only as AMP-007, the generic Atrovent HFA inhaler is now set for a Q2 launch with six months of exclusivity.
Generics Bulletin - March 9, 2026

Roche’s Predicted Mega-Blockbuster Giredestrant Faces Phase III Setback
Roche’s Phase III persevERA trial of giredestrant plus palbociclib in first-line ER-positive advanced breast cancer has missed its progression-free survival endpoint.
Scrip - March 9, 2026

Deals Shaping The Industry, February 2026
An interactive look at pharma, medtech and diagnostics deals made during February 2026. Data courtesy of Biomedtracker.
In Vivo - March 9, 2026

Estée Lauder Plans To Acquire Entire Stake Of Indian Brand Forest Essentials
The Estee Lauder Companies Inc. plans to acquire New Delhi-based luxury Ayurvedic beauty brand Forest Essentials in a transaction subject to regulatory approvals and that is expected to close in the second half of the year.
HBW Insight - March 9, 2026

Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: smaller companies consider European expansion under MFN; Pfizer CEO on FDA vaccine decisions; what does big pharma want from CRDMOs in AI age; neuroscience funding poised for comeback; and UCB’s big China deal.
Scrip - March 9, 2026

PDUFA VIII: US FDA Willing To Risk One-Time Potential Revenue Reduction In Five-Year Cycle
The agency offered to commission a third-party study of efficiency, workload and other factors to determine whether the base PDUFA revenue should be lowered mid-program cycle.
HBW Insight - March 9, 2026